Patents by Inventor Takashi Owa
Takashi Owa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8772269Abstract: The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.Type: GrantFiled: September 13, 2005Date of Patent: July 8, 2014Assignee: Eisai R&D Management Co., Ltd.Inventors: Takashi Owa, Yoichi Ozawa, Taro Semba
-
Patent number: 7834049Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.Type: GrantFiled: April 4, 2005Date of Patent: November 16, 2010Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
-
Publication number: 20100267754Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.Type: ApplicationFiled: June 10, 2010Publication date: October 21, 2010Inventors: Toshiaki WAKABAYASHI, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
-
Publication number: 20090227795Abstract: A method of measuring the binding activity of a test compound to a splicing factor 3b (SF3b), which comprises the following steps of: (a) contacting a labeled pladienolide compound and a test compound with a cell or a cell fraction; and (b) measuring the distribution of the bound labeled compound. The method enables to screen for a novel active compound capable of acting on (binding to) a pladienolide target molecule or the like.Type: ApplicationFiled: August 2, 2007Publication date: September 10, 2009Applicant: Eisai R & D Management Co., Ltd.Inventors: Yoshihiko Kotake, Koji Sagane, Takashi Owa, Yoshiharu Mizui, Hajime Shimizu, Yuko Kiyosue
-
Publication number: 20090047365Abstract: The present invention relates to a pharmaceutical composition, a kit, a method of treating cancer and/or a method of inhibiting angiogenesis comprising a sulfonamide compound in combination with a platinum complex, a DNA-topoisomerase I inhibitor, an antimetabolite, a microtubule inhibitor or an antibiotic.Type: ApplicationFiled: February 28, 2006Publication date: February 19, 2009Applicant: Eisai R & D Management Co., Ltd.Inventors: Takashi Owa, Yoichi Ozawa, Taro Semba, Naoko Hata
-
Publication number: 20090047278Abstract: The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer, comprising a sulfonamide compound in combination with a substance having an EGF inhibitory activity.Type: ApplicationFiled: February 28, 2006Publication date: February 19, 2009Applicant: Eisai R & D Management Co., Ltd.Inventors: Takashi Owa, Yoichi Ozawa, Taro Semba, Toshiaki Wakabayashi
-
Publication number: 20080286282Abstract: The present invention relates to a pharmaceutical composition, a kit and a method for treating cancer and/or a method for inhibiting angiogenesis, comprising a sulfonamide compound in combination with Bevacizumab.Type: ApplicationFiled: February 28, 2006Publication date: November 20, 2008Applicant: Eisai R & D Management Co., Ltd.Inventors: Taro Semba, Naoko Hata, Yoichi Ozawa, Takashi Owa
-
Patent number: 7445892Abstract: Susceptibility of a tumor cell to an anticancer agent is tested by measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in a tumor cell collected from a cancer patient treated with an anticancer agent (E7070 and related compounds thereof), or causing the anticancer agent to act on a tumor cell collected from a cancer patient and measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in the tumor cell, and determining that the tumor cell is susceptible to the anticancer agent when the expression level or levels of the gene or genes listed in Table 3 increase, or the expression level or levels of the gene or genes listed in Table 4 decrease.Type: GrantFiled: November 26, 2001Date of Patent: November 4, 2008Assignee: Eisai Co., Ltd.Inventors: Takashi Owa, Akira Yokoi, Junro Kuromitsu, Takatoshi Kawai, Hiroyuki Kato, Takeshi Nagasu
-
Publication number: 20060135486Abstract: The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.Type: ApplicationFiled: September 13, 2005Publication date: June 22, 2006Applicant: Eisai Co., Ltd.Inventors: Takashi Owa, Yoichi Ozawa, Taro Semba
-
Patent number: 7015241Abstract: An appetite-stimulating agent and a therapeutic agent for anorexia, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I): wherein the ring A represents a monocyclic or bicyclic aromatic ring which may be substituted, the ring B represents a 6-membered unsaturated hydrocarbon ring or a 6-membered unsaturated heterocyclic ring containing one nitrogen atom as a heteroatom, each of which may be substituted, the ring C represents a 5-membered heterocyclic ring containing one or two nitrogen atoms, which may be substituted, W represents a single bond or —CH?CH—, X represents —N(R1)— or an oxygen atom, Y represents a carbon atom or a nitrogen atom, Z represents —N(R2)— or a nitrogen atom, and R1 and R2 may be identical or different and each represents a hydrogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof, or a hydrate thereof.Type: GrantFiled: September 5, 2002Date of Patent: March 21, 2006Assignee: Eisai Co., Ltd.Inventors: Takashi Owa, Yoichi Ozawa, Takayuki Hida, Norimasa Miyamoto, Takeshi Nagasu, Tatsuo Okauchi, Hiroshi Yoshino, Naoko Hata, Kentaro Yoshimatsu, Nozomu Koyanagi, Kyosuke Kito
-
Publication number: 20050176712Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action.Type: ApplicationFiled: April 4, 2005Publication date: August 11, 2005Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
-
Publication number: 20040242628Abstract: An appetite-stimulating agent and a therapeutic agent for anorexia, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I): 1Type: ApplicationFiled: March 5, 2004Publication date: December 2, 2004Inventors: Takashi Owa, Yoichi Ozawa, Takayuki Hida, Norimasa Miyamoto, Takeshi Nagasu, Tatsuo Okauchi, Hiroshi Yoshino, Naoko Hata, Kentaro Yoshimatsu, Nozomu Koyanagi, Kyosuke Kito
-
Publication number: 20040235866Abstract: A lymphocyte activation inhibitor and a therapeutic agent for an autoimmune disease, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I): 1Type: ApplicationFiled: March 4, 2004Publication date: November 25, 2004Inventors: Takahisa Hanada, Toshihiko Yamauchi, Kenichi Chiba, Takashi Owa, Takayuki Hida, Norimasa Miyamoto
-
Patent number: 6787534Abstract: The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.Type: GrantFiled: June 10, 2002Date of Patent: September 7, 2004Assignee: Eisai Co., Ltd.Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Naoko Tsukahara, Takashi Owa
-
Publication number: 20040115664Abstract: Susceptibility of a tumor cell to an anticancer agent is tested by measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in a tumor cell collected from a cancer patient treated with an anticancer agent (E7070 and related compounds thereof), or causing the anticancer agent to act on a tumor cell collected from a cancer patient and measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in the tumor cell, and determining that the tumor cell is susceptible to the anticancer agent when the expression level or levels of the gene or genes listed in Table 3 increase, or the expression level or levels of the gene or genes listed in Table 4 decrease.Type: ApplicationFiled: May 23, 2003Publication date: June 17, 2004Inventors: Takashi Owa, Akira Yokoi, Junro Kuromitsu, Takatoshi Kawai, Hiroyuki Kato, Takeshi Nagasu
-
Publication number: 20040018192Abstract: The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.Type: ApplicationFiled: July 18, 2002Publication date: January 29, 2004Inventors: Toshiaki Wakabayashi, Yasuhiro Funahashi, Naoko Hata, Taro Semba, Yuji Yamamoto, Toru Haneda, Takashi Owa, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda
-
Patent number: 6673787Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1-C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1-C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded.Type: GrantFiled: March 18, 2002Date of Patent: January 6, 2004Assignee: Eisai Co., Ltd.Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Takashi Owa, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Noako Tsukahara
-
Patent number: 6638964Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof: In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1˜C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1˜C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded.Type: GrantFiled: March 18, 2002Date of Patent: October 28, 2003Assignee: Eisai Co., Ltd.Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Takashi Owa, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Noako Tsukahara
-
Publication number: 20030144507Abstract: The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.Type: ApplicationFiled: June 10, 2002Publication date: July 31, 2003Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Naoko Tsukahara, Takashi Owa
-
Patent number: 6469043Abstract: The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1˜C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1˜C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded.Type: GrantFiled: September 28, 2000Date of Patent: October 22, 2002Assignee: Eisai Co., Ltd.Inventors: Toru Haneda, Akihiko Tsuruoka, Junichi Kamata, Tadashi Okabe, Keiko Takahashi, Kazumasa Nara, Shinichi Hamaoka, Norihiro Ueda, Takashi Owa, Toshiaki Wakabayashi, Yasuhiro Funahashi, Taro Semba, Naoko Hata, Yuji Yamamoto, Yoichi Ozawa, Noako Tsukahara